- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
This Week in Managed Care: July 18, 2015
The top story was Marilyn Tavenner became the nation's top healthcare lobbyist when she was named the new president and CEO of America's Health Insurance Plans, plus the controversial new guidelines that called for more Americans to take statins were validated, according to the results of a new study.
This week the top story was the appointment of Marilyn B. Tavenner, former administrator for CMS, as the new president and chief executive officer of America's Health Insurance Plans (AHIP). Former AHIP President Karen Ignagni left the job in May for a new position with EmblemHealth. The new role will make Ms Tavenner, who was elected unanimously by the board of directors, the nation's top healthcare lobbyist.
Last week, the House voted overwhelmingly to pass the 21st Century Cures Act, which advances Big Data, strengthens the National Institutes of Health and precision medicine, and speeds the FDA approval process. The act promotes research in diseases that range from cancer, to multiple sclerosis, to ALS.
A new study in JAMA has validated the 2013 statin guidelines that caused much controversy when the American Heart Association and the American College of College of Cardiology issued them. The guidelines call for more Americans to take statins and the study found that the new guidelines are efficient and cost-effective.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
HMO and EPO Insurance Plans More Likely to Promote Use of Biosimilars
November 21st 2023Health plan type highly influences the likelihood of biosimilar uptake, with low-flexibility insurance plans more likely to have patients who either switched to a biosimilar or were initiated on a biosimilar.
Read More
Oncology Onward: A Conversation With Dr Debra Patt of Texas Oncology
August 1st 2023Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Listen
Therapists’ Perspectives on Access to Telemental Health Among Medicaid-Enrolled Youth
November 10th 2023This qualitative study elucidates therapists’ perspectives on barriers to and facilitators of access to telemental health among Medicaid-enrolled youth served by a large safety-net organization.
Read More
